Market ExpansionThe company has seen a steady increase in the number of patients completing prescription enrollment forms, indicating growing patient engagement and potential market expansion.
Pipeline DevelopmentWith multiple pivotal trials ongoing, including SCD with encouraging phase 2 data, Agios is positioning well for broad commercialization of Pyrukynd.
Regulatory MilestoneManagement plans to submit regulatory filings based on positive ENERGIZE and ENERGIZE-T results, aiming for a broad thalassemia label.